BACKGROUND: Information on prostate cancer testing and incidence among men under age 50 is scant. This study aims to describe trends of prostate cancer testing and incidence by demographic and clinical characteristics and identify potential correlations between prostate cancer testing and incidence. METHODS: We examined prostate cancer testing and incidence rates among American men under age of 50 using data from the Behavioral Risk Factor Surveillance System (2002, 2004, 2006, and 2008) and data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results programs (2001-2006). We conducted descriptive, logistic regression, and trend analyses using SUDAAN and SEER*Stat. RESULTS: The prostate cancer incidence rate among black men was more than 2-fold that of white men. The overall prostate cancer incidence rate slightly increased from 2001 to 2006; however, the prevalence of prostate cancer testing declined over time. There was a borderline significant increase in prostate cancer incidence rate (APC=3.5, 95% CI=0.0, 7.0) for men aged 40-44. Well-differentiated prostate cancer incidence decreased significantly (APC=-24.7; 95% confidence interval (CI)=-34.9, -12.8) over time. CONCLUSIONS: We observed a large difference in prostate cancer incidence between blacks and whites under age 50. Similar patterns in prostate cancer testing and cancer incidence by race and ethnicity suggested prostate cancer testing might have influenced incidence to some extent in this young population. The different temporal patterns for prostate cancer testing and incidence, especially for men aged 40-44 years, suggested screening alone could not fully accounted for the increasing prostate cancer incidence rates. Decreasing trend of well-differentiated prostate cancer may be partially due to "Grade Inflation". Published by Elsevier Ltd.
BACKGROUND: Information on prostate cancer testing and incidence among men under age 50 is scant. This study aims to describe trends of prostate cancer testing and incidence by demographic and clinical characteristics and identify potential correlations between prostate cancer testing and incidence. METHODS: We examined prostate cancer testing and incidence rates among American men under age of 50 using data from the Behavioral Risk Factor Surveillance System (2002, 2004, 2006, and 2008) and data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results programs (2001-2006). We conducted descriptive, logistic regression, and trend analyses using SUDAAN and SEER*Stat. RESULTS: The prostate cancer incidence rate among black men was more than 2-fold that of white men. The overall prostate cancer incidence rate slightly increased from 2001 to 2006; however, the prevalence of prostate cancer testing declined over time. There was a borderline significant increase in prostate cancer incidence rate (APC=3.5, 95% CI=0.0, 7.0) for men aged 40-44. Well-differentiated prostate cancer incidence decreased significantly (APC=-24.7; 95% confidence interval (CI)=-34.9, -12.8) over time. CONCLUSIONS: We observed a large difference in prostate cancer incidence between blacks and whites under age 50. Similar patterns in prostate cancer testing and cancer incidence by race and ethnicity suggested prostate cancer testing might have influenced incidence to some extent in this young population. The different temporal patterns for prostate cancer testing and incidence, especially for men aged 40-44 years, suggested screening alone could not fully accounted for the increasing prostate cancer incidence rates. Decreasing trend of well-differentiated prostate cancer may be partially due to "Grade Inflation". Published by Elsevier Ltd.
Authors: Cindy Ke Zhou; David P Check; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Jacques Ferlay; Freddie Bray; Michael B Cook; Susan S Devesa Journal: Int J Cancer Date: 2015-11-27 Impact factor: 7.396
Authors: Behfar Ehdaie; Bing Ying Poon; Daniel D Sjoberg; Pedro Recabal; Vincent Laudone; Karim Touijer; James Eastham; Peter T Scardino Journal: BJU Int Date: 2015-10-26 Impact factor: 5.588
Authors: Mary C White; Lucy A Peipins; Meg Watson; Katrina F Trivers; Dawn M Holman; Juan L Rodriguez Journal: J Adolesc Health Date: 2013-05 Impact factor: 5.012
Authors: Marianne Schmid; Quoc-Dien Trinh; Markus Graefen; Margit Fisch; Felix K Chun; Jens Hansen Journal: World J Urol Date: 2014-05-14 Impact factor: 4.226
Authors: Michael Blaise Cook; Zhaoming Wang; Edward D Yeboah; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Ann Truelove; Shelley Niwa; Charles C Chung; Annand P Chokkalingam; Lisa W Chu; Meredith Yeager; Amy Hutchinson; Kai Yu; Kristin A Rand; Christopher A Haiman; Robert N Hoover; Ann W Hsing; Stephen J Chanock Journal: Hum Genet Date: 2013-11-02 Impact factor: 4.132
Authors: N J Kinnear; G Kichenadasse; S Plagakis; M E O'Callaghan; T Kopsaftis; S Walsh; D Foreman Journal: World J Urol Date: 2016-04-12 Impact factor: 4.226
Authors: Natasha D Buchanan; Jessica B King; Juan L Rodriguez; Arica White; Katrina F Trivers; Laura P Forsythe; Erin E Kent; Julia H Rowland; Susan A Sabatino Journal: ISRN Oncol Date: 2013-06-16